CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Yield10 Bioscience, Inc.  (MBLX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

MBLX's Revenue Growth by Quarter and Year

Yield10 Bioscience,'s Revenue results by quarter and year




MBLX Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December 0.50 0.10 -2.78 0.50
III Quarter September 0.08 0.22 0.47 0.71
II Quarter June 0.29 0.29 2.79 0.74
I Quarter March 0.06 0.32 0.68 0.65
FY   0.93 0.93 1.16 2.60



MBLX Revenue forth quarter 2018 Y/Y Growth Comment
Yield10 Bioscience, Inc. achieved in the forth quarter, above Company average Revenue surge of 396% year on year, to $ 0.50 millions.

According to the results reported in the forth quarter, Yield10 Bioscience, Inc. achieved the best Revenue growth in Medical Laboratories industry. While Yield10 Bioscience, Inc.' s Revenue doubling of 396% ranks overall at the positon no. 43 in the forth quarter.




MBLX Revenue ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December 396 % - - -
III Quarter September -63.64 % -53.19 % -33.8 % 12.7 %
II Quarter June 0 % -89.61 % 277.03 % -36.75 %
I Quarter March -81.25 % -52.94 % 4.62 % -39.25 %
FY   -0.43 % -19.83 % -55.38 % -

Financial Statements
Yield10 Bioscience,'s forth quarter 2018 Revenue $ 0.50 millions MBLX's Income Statement
Yield10 Bioscience,'s forth quarter 2017 Revenue $ 0.10 millions Quarterly MBLX's Income Statement
New: More MBLX's historic Revenue Growth >>


MBLX Revenue (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December 520 % -54.55 % - -29.58 %
III Quarter September -72.41 % -24.14 % -83.15 % -4.05 %
II Quarter June 383.33 % -9.38 % 310.29 % 13.85 %
I Quarter March -40 % - 36 % -
FY (Year on Year)   -0.43 % -19.83 % -55.38 % -




Revenue forth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #18
Overall #43

Revenue Y/Y Growth Statistics
High Average Low
552.63 % 23.56 % -100 %
(Dec 31 2018)   (Jun 30 2018)
Revenue forth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #18
Overall #43
Revenue Y/Y Growth Statistics
High Average Low
552.63 % 23.56 % -100 %
(Dec 31 2018)   (Jun 30 2018)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Yield10 Bioscience,'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
552.63 % 40 % -97.65 %
(Dec 31 2018)  


MBLX's IV. Quarter Q/Q Revenue Comment
Yield10 Bioscience, Inc. achieved in the IV. Quarter 2018 above company average sequential Revenue doubling of 520%, to $ 0.50 millions, from $0.08 millions in the third quarter.
Medical Laboratories company is going from strength to strength, with recording better then average growth, but also improving speed.

Within Medical Laboratories industry Yield10 Bioscience, Inc. achieved highest sequential Revenue growth. While Yield10 Bioscience,'s Revenue growth quarter on quarter, overall rank is 46.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #18
Overall #46
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #1
Healthcare Sector #18
Overall #46
Revenue Q/Q Growth Statistics
High Average Low
552.63 % 40 % -97.65 %
(Dec 31 2018)  


MBLX's IV. Quarter Q/Q Revenue Comment
Yield10 Bioscience, Inc. achieved in the IV. Quarter 2018 above company average sequential Revenue doubling of 520%, to $ 0.50 millions, from $0.08 millions in the third quarter.
Medical Laboratories company is impressively improving, not just claiming higher then average gain, and also accelerating pace.

Within Medical Laboratories industry Yield10 Bioscience, Inc. achieved highest sequential Revenue growth. While Yield10 Bioscience,'s Revenue growth quarter on quarter, overall rank is 46.


Yield10 Bioscience,'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2018)
12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.67 $ 0.68 $ 0.94
Y / Y Revenue Growth (TTM) - - - -15.84 % -18.55 %
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - -1.18 % -27.97 % -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #




Cumulative Revenue growth Comment
Yield10 Bioscience, Inc. realized trailing twelve months of $ 0 millions, in the Dec 31 2018, compare to Revenue of $ 1 millions a year ago.

Yield10 Bioscience, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
Yield10 Bioscience, Inc. realized trailing twelve months of $ 0 millions, in the Dec 31 2018, compare to Revenue of $ 1 millions a year ago.

Yield10 Bioscience, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MBLX's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for MBLX's Competitors
Revenue Growth for Yield10 Bioscience,'s Suppliers
Revenue Growth for MBLX's Customers

You may also want to know
MBLX's Annual Growth Rates MBLX's Profitability Ratios MBLX's Asset Turnover Ratio MBLX's Dividend Growth
MBLX's Roe MBLX's Valuation Ratios MBLX's Financial Strength Ratios MBLX's Dividend Payout Ratio
MBLX's Roa MBLX's Inventory Turnover Ratio MBLX's Growth Rates MBLX's Dividend Comparisons



Companies with similar Revenue doubling for the quarter ending Dec 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2018
Acadia Pharmaceuticals Inc  599.84 %$ 599.837 millions
Ultragenyx Pharmaceutical Inc.  573.61 %$ 573.612 millions
Cure Pharmaceutical Holding Corp.  564.86 %$ 564.863 millions
Novan, Inc.  549.92 %$ 549.919 millions
Mei Pharma, Inc.  472.07 %$ 472.067 millions
Ctd Holdings Inc  382.83 %$ 382.829 millions
Hemispherx Biopharma Inc  380.00 %$ 380.000 millions
Yield10 Bioscience, Inc.  376.92 %$ 376.923 millions
Bluebird Bio, Inc.  361.68 %$ 361.684 millions
Can-fite Biopharma Ltd.  351.00 %$ 351.004 millions
Biocardia, Inc.  326.00 %$ 326.000 millions
Ibio, Inc.  325.49 %$ 325.490 millions
Geovax Labs, Inc.  313.54 %$ 313.538 millions
Editas Medicine, Inc.  291.49 %$ 291.492 millions
Vilacto Bio Inc.  291.30 %$ 291.304 millions
Vet Online Supply Inc  286.28 %$ 286.282 millions
Aclaris Therapeutics, Inc.  267.27 %$ 267.267 millions
Portola Pharmaceuticals Inc  258.43 %$ 258.435 millions
Bionik Laboratories Corp.  256.47 %$ 256.475 millions
Mannkind Corp  253.91 %$ 253.907 millions
Anavex Life Sciences Corp.  251.37 %$ 251.366 millions
Seres Therapeutics, Inc.  247.81 %$ 247.808 millions
Paratek Pharmaceuticals, Inc.  237.28 %$ 237.283 millions
Heat Biologics, Inc.  235.40 %$ 235.403 millions
Sunshine Biopharma, Inc  232.87 %$ 232.866 millions
Cardax, Inc.  229.13 %$ 229.125 millions
Puma Biotechnology, Inc.  228.95 %$ 228.948 millions
Beigene, Ltd.  222.82 %$ 222.824 millions
Mynd Analytics, Inc.  217.30 %$ 217.295 millions
Livanova Plc  208.97 %$ 208.968 millions


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BNKL's Profile

Stock Price

BNKL's Financials

Business Description

Fundamentals

Charts & Quotes

BNKL's News

Suppliers

BNKL's Competitors

Customers & Markets

Economic Indicators

BNKL's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2019 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071